Biography

Dr. Jiang-Jiang Qin is currently a Professor and Principal Investigator at the Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences. He also serves as the Deputy Director of the Center for Innovative Drug Research. Dr. Qin received his B.S. degree in Pharmacy (2006) and Ph.D. in Biomedical Engineering with the highest honor (2011) from Shanghai Jiao Tong University, China, under the supervision of Professor Wei-Dong Zhang. After completion of post-doctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC) in 2014, Dr. Qin continued his research work at TTUHSC as a Research Associate and a Senior Research Associate and at the University of Houston as a Senior Research Scientist. Dr. Qin joined Zhejiang Chinese Medicinal University as a Full Professor in 2018 and then moved to HIM in 2020. 

Research Interests

Dr. Qin has significant expertise in cancer biology, cancer pharmacology, natural product chemistry, and medicinal chemistry. His laboratory focuses on discovering new cancer biomarkers and drug targets by applying innovative bioinformatics approaches, elucidating the molecular mechanisms underlying the development, progression, metastasis, and drug resistance of human cancer, especially gastric and pancreatic cancer, and developing novel, effective, and safe anticancer agents by utilizing state-of-the-art technologies. Dr. Qin has established successful collaborations with basic and clinical scientists, physicians, clinicians, and industries. His long-term goals are to translate basic science discoveries into innovative diagnostic and therapeutic strategies, finally improving the care and management of patients with malignant tumors, especially gastric and pancreatic cancer.

Selected Publications

(1) Atlas of metastatic gastric cancer links ferroptosis to disease progression and immunotherapy response.

Xiangdong Cheng#, Enyu Dai#, Jibo Wu#, Natasha M Flores, Yanshuo Chu, Ruiping Wang, Minghao Dang, Zhiyuan Xu, Guangchun Han, Yunhe Liu, Deyali Chatterjee, Can Hu, Jieer Ying, Yian Du, Litao Yang, Xiaoqing Guan, Shaowei Mo, Xuanye Cao, Guangsheng Pei, Jiahui Jiang, Xiaoyin Lu, Ana Morales Benitez, Rebecca E Waters, Melissa Pool Pizzi, Namita Shanbhag, Yibo Fan, Fuduan Peng, Samir M Hanash, George Calin, Andrew Futreal, Shumei Song, Cassian Yee, Pawel K Mazur*, Jiang-Jiang Qin*, Jaffer A Ajani*, Linghua Wang*. Gastroenterology. 2024 Aug 1:S0016-5085(24)05297-1. doi: 10.1053/j.gastro.2024.07.038. Online ahead of print.

(2) Blocking Ubiquitin-Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoA Desaturase.

Xiaoqing Guan#, Yichao Wang#, Wenkai Yu, Yong Wei, Yang Lu, Enyu Dai, Xiaowu Dong, Bing Zhao, Can Hu, Li Yuan, Xin Luan, Kai Miao, Bonan Chen, Xiang-Dong Cheng*, Weidong Zhang*, Jiang-Jiang Qin*. Advanced Science 2024; 1870(1): 166884. 

(3) ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation.

Furong Ma#, Yulong Li#, Maohua Cai, Wenyan Yang, Zumei Wu, Jinyun Dong*, Jiang-Jiang Qin*.  European Journal of Medicinal Chemistry 2024; 270: 116387.

(4) Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. 

Ruiping Wang#, Shumei Song#, Jiang-Jiang Qin#, Katsuhiro Yoshimura, Fuduan Peng, Yanshuo Chu, Yuan Li, Yibo Fan, Jiankang Jin, Minghao Dang, Enyu Dai, Guangsheng Pei, Guangchun Han, Dapeng Hao, Yating Li, Deyali Chatterjee, Kazuto Harada, Melissa Pool Pizzi, Ailing W Scott, Ghia Tatlonghari, Xinmiao Yan, Zhiyuan Xu, Can Hu, Shaowei Mo, Namita Shanbhag, Yang Lu, Matheus Sewastjanow-Silva, Ahmed Adel Fouad Abdelhakeem, Guang Peng, Samir M Hanash, George A Calin, Cassian Yee, Pawel Mazur, Autumn N Marsden, Andrew Futreal, Zhenning Wang, Xiangdong Cheng, Jaffer A Ajani*, Linghua Wang*. Cancer Cell. 2023; 41(8): 1407-1426.e9.

(5) Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.  

Shengli Li#, Li Yuan#, Zhi-Yuan Xu, Jing-Li Xu, Gui-Ping Chen, Xiaoqing Guan, Guang-Zhao Pan, Can Hu, Jinyun Dong, Yi-An Du, Li-Tao Yang, Mao-Wei Ni, Rui-Bin Jiang, Xiu Zhu, Hang Lv, Han-Dong Xu, Sheng-Jie Zhang, Jiang-Jiang Qin*, Xiang-Dong Cheng*. Nature Communications 2023; 14:778. 

(6) Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer.

Xiaoqing Guan#, Jing Yang#, Weiyi Wang#*, Bing Zhao, Shiyu Hu, Dehua Yu, Li Yuan, Yunfu Shi, Jingli Xu, Jinyun Dong, Jinxin Wang, Xiang-Dong Cheng*, Jiang-Jiang Qin*. Pharmacological Research 2023; 189:106703.

(7) Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis.

Simin Qi#, Xiaoqing Guan#, Jia Zhang#, Dehua Yu, Xuefei Yu, Qinglin Li, Wenjuan Yin, Xiang-Dong Cheng*, Weidong Zhang*, Jiang-Jiang Qin*. Molecular Cancer 2022; 21:70.

(8) Targeting KRAS mutant cancers: From druggable therapy to drug resistance.

Chunxiao Zhu#, Xiaoqing Guan#, Xinuo Zhang#, Xin Luan, Zhengbo Song, Xiang-Dong Cheng*, Weidong Zhang*, Jiang-Jiang Qin*. Molecular Cancer 2022; 21: 159.

(9) Protein degradation technology: A strategic paradigm shift in drug discovery.  

Haobin Li#, Jinyun Dong#*, Maohua Cai, Zhiyuan Xu, Xiang-Dong Cheng*, Jiang-Jiang Qin*. Journal of Hematology & Oncology 2021; 14:138.

(10) Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.

Jinyun Dong#, Zuodong Qin#, Wei-Dong Zhang, Gang Cheng, Assaraf G Yehuda, Charles R Ashby Jr, Zhe-Sheng Chen*, Xiang-Dong Cheng*, Jiang-Jiang Qin*. Drug Resistance Updates 2020; 49:100681.

Contacts

E-mail: qinjiangjiang@him.cas.cn or jqin@ucas.ac.cn

Website:https://www.x-mol.com/groups/qin_lab?lang=zh

Hangzhou Institute of Medicine

Chinese Academy of Science

150 Fucheng Road, Qiantang District

Hangzhou, Zhejiang Province, China 310000